Skip to main content
VERA
NASDAQ Life Sciences

Vera 10-Q: First TRUTAKNA Revenue $10.3M, Cash $384M, Q4 Charge of Up to $14.6M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$29.529
Mkt Cap
$2.172B
52W Low
$23.05
52W High
$56.05
52W Position info
28% above low
Off High info
47% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

VERA sits 28% above its 52-week low of $23.05.

Summary

Vera's Q3 10-Q shows first TRUTAKNA revenue of $10.3 million, a $93.7 million net loss, and $384.0 million of cash that rises to about $459 million pro forma after an October $75 million debt draw. The company also flagged a Q4 charge of up to $14.6 million from cancelled R&D manufacturing.


Key Events · Earnings and Guidance · VERA

  • First TRUTAKNA Quarter: $10.3M Revenue

    Net product revenue of $10.3 million in Q3 2026, the first quarter with product sales, versus none a year earlier. Cost of sales was $3.3 million, low because pre-approval inventory had already been expensed to R&D.

  • Net Loss $93.7M, SG&A Up 124%

    Net loss of $93.7 million, or $1.30 per share, versus $80.3 million a year earlier. SG&A rose to $61.4 million from $27.5 million on launch spending, while R&D fell to $41.3 million from $56.5 million as manufacturing costs moved to inventory.

  • Cash $384M; $75M Debt Draw in October

    Cash, cash equivalents and marketable securities were $384.0 million at September 30, 2026, down from $714.6 million at December 31, 2025. The October draw of the Oxford tranche added $74.0 million net, taking outstanding debt to $150.0 million and pro forma cash to about $459 million.

  • Q4 Charge of Up to $14.6M

    In October 2026 Vera cancelled certain scheduled R&D manufacturing activities and expects a loss of up to $14.6 million, to be recognized as R&D expense in the three months ending December 31, 2026. Minimum purchase obligations to manufacturers were $88.1 million at quarter end.


Analysis · VERA · Life Sciences

The full financial picture behind the Q3 earnings release filed the same day. TRUTAKNA's first commercial quarter produced $10.3 million of net product revenue against $3.3 million of cost of sales, but that gross margin is flattered: pre-approval inventory was expensed to R&D, so the cost basis of what was sold was near zero. The real story is the spending curve. SG&A more than doubled to $61.4 million in the quarter as Vera built a sales force, while R&D fell 27% to $41.3 million because manufacturing costs moved into inventory. Cash fell to $384.0 million from $714.6 million at year-end, and the company drew the $75 million Oxford tranche in October for $74.0 million net, taking debt to $150.0 million and pro forma cash to roughly $459 million. Against that, Vera disclosed a new charge: it cancelled certain R&D manufacturing activities in October and expects a loss of up to $14.6 million in Q4. It also carries $88.1 million of minimum purchase obligations to manufacturers. The runway statement covers at least the next 12 months, but the burn rate and the launch spend mean another raise is likely before profitability.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VERA was trading at $29.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $23.05 to $56.05. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VERA - Latest Insights

VERA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.07
Real-time Price: $24.88 info
Change: -$6.19 (-20%) info
Market Cap: $1.84B info
VERA
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $30.98
Real-time Price: $24.88 info
Change: -$6.10 (-20%) info
Market Cap: $1.84B info
VERA
Sep 15, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $38.64
Real-time Price: $24.88 info
Change: -$13.76 (-36%) info
Market Cap: $1.84B info
VERA
Sep 15, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $37.69
Real-time Price: $24.88 info
Change: -$12.81 (-34%) info
Market Cap: $1.84B info
VERA
Aug 10, 2026, 5:07 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $31.50
Real-time Price: $24.88 info
Change: -$6.62 (-21%) info
Market Cap: $1.84B info